Inhibikase Therapeutics, Inc.

IKT

CIK 0001750149 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$1M
↑+30.8% +$245Kvs FY2024 (Q4)
Gross Profit
$1M
↑+30.8% +$245Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
50/100
  • Profitability
    0ROIC -30.7% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 21.70 (above 1.5 = solid)
  • Leverage
    98D/E 0.03 (under 0.5 = conservative)
  • Efficiency
    0Asset Turnover 0.03x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +30.8% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$13K
investment in PP&E
Stock-based comp (TTM)
$15M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$181M
everything owned
Total liabilities
$8M
everything owed
Stockholders' equity
$173M
shareholder claim
Net debt
$-178M
Net cash position ($178M)

Recent performance · 24 quarters

Revenue↑+30.8% +$245K
$1M
Net Income↓-106.5% -$6M
$-12M
Free Cash Flow
$0
Operating Margin↑+55906.2pts
-5993.4%

Drill down